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Friday, June 24, 2011  
12:00 pm – 4:15 pm 
 
Farrell Teaching and Learning Center 
Connor Auditorium 




12:00 pm  Welcome 
 Jonathan Green, MD, Executive Chair, Human Research Protection Office 
 
12:10 – 1:30 pm Device Advice 
Lynn Henley, MS, MBA, IDE and HDE Programs 
Office of Device Evaluation, Center for Devices and Radiological Health, FDA 
 
Topics to be addressed:  
• How to distinguish when “standard care” use of a device is research. 
• Determining if a device is “exempt” from the IDE regulations 
• Who makes the first risk determination? 
• Pre-IDE application: What is it? What does it encompass? 
• Significant vs. non-significant risk 
• Responsibilities of the investigator, sponsor and investigator-sponsor 
o Responsibilities related to disposal, storage and handling when the PI is 
going to handle this. 
 PI responsibilities 
 Institutional responsibilities 
• What is looked for in an FDA audit of a device? 
• Humanitarian Use Devices 
o Responsibilities of the IRB and investigator when there is a Premarket 
Approval 
o Responsibilities of the IRB and investigator when there is not a Premarket 
Approval 
o What is a Premarket approval? 
o FDA wants additional safety data on a HUD. What does this mean? Is this 
research? Responsibilities of the investigator and IRB. 
• Transitional Devices – what are they? 
 
1:30 – 2:00 pm  Billing and Compliance Issues with Devices 
 Carlos Brown, MSHA, Compliance Director 
Patient and Clinical Trials, Barnes-Jewish Hospital  
            
 Yi Zhang, JD, RN, Assistant Dean Clinical Studies 
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2:00 – 2:30 pm   IRB Requirements in the Review of Device Studies 
 Jonathan Green, MD, Executive Chair, Human Research Protection Office 
Washington University Human Research Protection Office 
 
2:30 – 2:45 pm      Break 
 
2:45 – 3:15 pm  The Importance of Device Accountability  
Colin Derdeyn, MD, Professor of Radiology, Neurology and Neurological Surgery, 
Washington University School of Medicine 
 
3:15 – 4:15 pm  Panel Discussion  
Facilitator: 
Jonathan Green, MD, Executive Chair, Human Research Protection Office 
 
FDA representative: 
Lynn Henley, MS, MBA, IDE and HDE Programs 
 
Investigators:  
Colin Derdeyn, MD, Professor of Radiology, Neurology and Neurological Surgery 
Jin-Moo Lee, MD, PhD,   Associate Professor; Director, Cerebrovascular Disease  
Darryl Zuckerman, MD,  Assistant Professor of Radiology and Surgery 
 
Research Administrators: 
Martha Jones, MA, CIP, Executive Director, Human Research Protection Office  
Yi Zhang, JD, RN, Assistant Dean Clinical Studies 
  
Research Operations:  




4:15 pm  Wrap up and Evaluations 
 
This event is sponsored by the Human Research Protection Office, Center for Clinical Studies, 
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Speakers, in alphabetical order: 
Carlos Brown, MSHA, Compliance Director, Patient and Clinical Trials, Barnes-Jewish Hospital 
 
Mr. Brown has designed, directed and overseen the day to day operations for program and 
policies that ensure successful corporate compliance, HIPAA privacy and clinical trials 
operations since taking his position in 2007. Mr. Brown has helped Barnes Jewish Hospital 




Colin Derdeyn, MD, Professor of Radiology, Neurology and Neurological Surgery, Washington 
University School of Medicine 
 
Dr. Derdeyn has experience with medical devices and the FDA approval process for them on 
many levels. His clinical specialty, interventional neuroradiology, is dependent on medical 
devices. This specialty, also known as endovascular neurosurgery, uses x-ray guidance and 
catheters (tubes) guided into brain arteries to place devices to treat patients with brain 
aneurysms, stroke and other forms of cerebrovascular disease. New devices are frequently 
developed for these challenging problems. He is the immediate past president of the medical 
society for physicians in this specialty, the Society of NeuroInterventional Surgery. He has been 
a consultant to the FDA Panel for Neurological Devices for the past 8 years. He is the Neuro-
Interventional Principal Investigator of the Stenting versus Aggressive Medical Management for 
Prevention of Recurrent Ischemic Stroke (SAMMPRIS) trial, the first NIH-funded randomized 
trial of an intracranial medical device (angioplasty and stent) for stroke risk reduction in patient 
with atherosclerotic disease of the intracranial arteries. He chairs the Data and Safety 
Monitoring Boards for two NIH-funded stroke treatment trials involving medical devices (MR-
Rescue and Ictus-L). He is on the Scientific Advisory Board of W.L. Gore and Associates and 
chairs the SAB for Pulse Therapeutics, two medical device companies. Locally, Dr. Derdeyn 
directs the Stroke and Cerebrovascular Center at Washington University and Barnes Jewish 
Hospital. He has been a local site investigator for many FDA IDE trials as well. 
 
Jonathan Green, MD, Executive Chair, Human Research Protection Office, Washington 
University 
 
Dr. Green is Associate Professor of Medicine and he is engaged in both laboratory and clinical 
research.  He has broad experiences in clinical research and human subjects protection having 
previously served as an IRB committee Vice Chair and as a member and Chair of the Barnes-
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Lynn Henley, MS, MBA, IDE and HDE Programs, Office of Device Evaluation, Center for 
Devices and Radiological Health, FDA  
 
Ms. Henley has degrees in Biology, Biotechnology and Business. She has spoken to numerous 
groups at academic institutions (Stanford University, University of Pittsburgh Medical Center), 
conferences (Columbia University IRB Conference, MD&M West), government research 
facilities (National Institutes of Health, Fort Detrick) and regulatory workshops (Regulatory 
Affairs Professional Society, AdvaMed) concerning Investigational Device Exemptions and 
Humanitarian Device Exemptions.  At CDRH, she serves on the Clinical Expert Review 
Committee, participate in the Level of Evidence Project, and represent the Office of Device 
Evaluation at CDISC. 
 
 
Martha Jones, MA, CIP, Executive Director, Human Research Protection Office, Washington 
University  
Ms. Jones is currently the Executive Director of the Human Research Protection Office (HRPO) 
at Washington University in St. Louis. She is also a site visitor with the Association for the 
Accreditation of Human Research Protection Programs (AAAHRP) and is currently an 
Accreditation Team Leader. Ms. Jones has served on Conflict of Interest committees, as a 
member of internal advisory committees and clinical trials billing task forces. 
Jin-Moo Lee, MD, PhD,   Associate Professor; Head, Cerebrovascular Disease Section, 
Washington University  
Dr. Lee’s areas of specialty are: Adult Neurology, Cerebrovascular Disease and  
Stroke.  In particular his clinical interests are in the areas of  stroke, ischemic brain injury, 
intracerebral hemorrhage, and stroke in young patients. He has conducted many research 
studies and published numerous papers within his specialty areas. Many of those have dealt 
with investigational devices. 
Kristin Luepke, RN, MSN, CCRC, Manager of Research Operations, Division of General 
Surgery, Washington University  
Ms. Luepke assists and directs administration of all aspects of multiple general surgery research 
trials, both drug and device studies. Ms. Luepke works with general surgery faculty and 
research staff in planning and conducting clinical research activities including: budgetary 
planning and negations, billing compliance, funding, accounting, contracting, financial 
management and oversight, regulatory documentation, IRB and FDA adherence, education and 
training.  
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Yi Zhang, JD, RN, Assistant Dean Clinical Studies, Center for Clinical Studies, Washington 
University  
 
As assistant dean for clinical studies, Ms. Zhang plans, directs and oversees clinical trials 
activities at the School of Medicine. She manages the negotiation of industry-sponsored clinical 
trial contracts and works with various institutional offices and stakeholders to assure 
compliance, including clinical trial billing compliance, with regulations, policies and laws, as well 
as coordinate federal clinical trials with the Grants and Contracts Office and the Research 
Office. Ms. Zhang leads the administrative core and manges the operations for the Center for 
Applied Research Sciences with its director.  
 
Darryl Zuckerman, MD, Assistant Professor of Radiology and Surgery, Washington University 
 
Dr. Zuckerman is a physician who, on occasion, treats patients with investigational devices. In 
this capacity, Dr. Zuckerman interfaces with nurses and other physicians as well as lay people 
and third party payors to facilitate such treatments. One of Dr. Zuckerman’s projects has been 
to bring a device known as “TheraSpheres” to Washington University and BJH. These 
radioactive microspheres, designed for localized delivery of radiation to liver tumors, are 
approved by the FDA under a Humanitarian Device Exemption and as such, require local IRB 
oversight 
 
Planning Committee, in alphabetical order:  
Sally Anderson, RN, BSN, CCRC, CTSA Research Navigator, Washington University 
Christy Auston, MA, CIP, Washington University 
Sarah Fowler-Dixon, PhD, CIP, Education Specialist, Human Research Protection Office, 
Washington University 
Martha Jones, MA, CIP, Executive Director, Human Research Protection Office, Washington 
University 
Jeanne Velders, JD, CIP, Associate Director, Human Research Protection Office, Washington 
University 
Yi Zhang, JD, Assistant Dean Clinical Studies, Center for Clinical Studies, Washington 
University  
